Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome

References

• Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012;119:5632–5639.
   PubMed Web of Science ®Google Scholar
• Parmar S, de Lima M, Deeg HJ, et al. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol 2011;38:693–704.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu K, Xu L, et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 2010;45:1333–1339.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant 2013;19:180–184.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol 2012;19:454–461.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004;125:217–224.
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007;21:2145–2152.
   PubMed Web of Science ®Google Scholar
• Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107:1688–1695.
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:1216–1223.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. Am J Hematol 2011;86:227–230.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Influence of lymphocyte recovery on outcome of haploidentical transplantation for hematologic malignancies. Medicine (Baltimore) 2009;88:322–330.
   Google Scholar
• Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008;14:323–334.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Jiang Y, et al. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2011;17: 1169–1175.
   PubMed Web of Science ®Google Scholar
• Federmann B, Hagele M, Pfeiffer M, et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011;25:121–129.
   PubMed Web of Science ®Google Scholar
• Kesserwan C, Munchel A, Kos F, et al. Immune reconstitution after nonmyeloablative, T-cell replete, HLA-haploidentical BMT with post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2011;17:S230–S231.
   Web of Science ®Google Scholar
• Bosch M, Khan FM, Storek J. Immune reconstitution after hema-topoietic cell transplantation. Curr Opin Hematol 2012;19:324–335.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huo MR, et al. Immune reconstitution following unmanipulated HLA-mismatched/haploidentical trans-plantation compared with HLA-identical sibling transplantation. J Clin Immunol 2012;32:268–280.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250–259.
   PubMed Web of Science ®Google Scholar
• Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380–3389.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks:new representations of old estimators. Stat Med 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119:3256–3262.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–2100.
   PubMed Web of Science ®Google Scholar
• Nguyen S, Beziat V, Norol F, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation. Transfusion 2011;51:1769–1778.
   PubMed Web of Science ®Google Scholar
• Jacobs NL, Holtan SG, Porrata LF, et al. Host immunity affects survival in myelodysplastic syndromes: independent prognostic value of the absolute lymphocyte count. Am J Hematol 2010;85:160–163.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011;52:49–57.
   PubMed Web of Science ®Google Scholar
• Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011;118: 5965–5976.
   PubMed Web of Science ®Google Scholar
• Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies:posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009;113:4771–4779.
   PubMed Web of Science ®Google Scholar
• Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes:outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99:1943–1951.
   PubMed Web of Science ®Google Scholar
• Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome:a retrospective analysis. Lancet Oncol 2011;12:1214–1221.
   PubMed Web of Science ®Google Scholar
• Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol 2004;11:386–391.
   PubMed Web of Science ®Google Scholar
• Dong L, Wu T, Zhang MJ, et al. CD3 + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007;13:1515–1524.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Xu LL, Lu SY, et al. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 2011;41:514–526.
   PubMed Web of Science ®Google Scholar